Abstract 1495P
Background
Socially isolated patients have a higher early mortality rate across multiple cancers. However, there have been no reports on how social isolation such as solitary life affects the clinical outcomes in advanced non-small cell lung cancer (NSCLC).
Methods
We conducted a retrospective analysis of patients with advanced NSCLC who received systemic therapy at the National Cancer Center (NCC) between January 2021 and December 2023. This study assessed the association between social isolation, such as living alone, and clinical outcomes, including overall survival (OS) and the incidence of serious adverse events (SAE) during systemic treatment. Additionally, we evaluated the transition rates to palliative care, both at home and in palliative care units (PCU), as well as the proportion of in-hospital deaths at our institution.
Results
During the study period, 679 patients initiated systemic treatment for advanced NSCLC. Of these, 119 patients were living alone (alone group) while the remaining 560 were not (non-alone group). The median age was comparable between the alone and non-alone groups (63 vs. 67 years, p=0.20), but the alone group had a higher proportion of females (46.2% vs. 37.5%, p=0.08). Regarding the driver genetic alterations, there was no significant difference between the two groups in the presence of EGFR mutations (36.1% vs. 32.1%, p=0.70) and ALK rearrangement (7.4% vs. 5.3%, p=0.66). Treatment modalities were also comparable between the alone group and non-alone groups for TKI use (44.1% vs. 39.5%, p=0.86). The alone group showed numerically better outcomes in OS and SAE rates than the non-alone group (OS: not reached vs. 50.7 months, p=0.11; and SAE: 10.9% vs. 18.8%, p=0.08). In the alone group, the transition rates to palliative care at home was significantly lower (13.0% vs. 32.0%, p=0.04), and the proportion of in-hospital deaths (NCC or PCU) was higher compared with non-alone group (82.6% vs. 66.7%, p=0.04).
Conclusions
Social isolation such as living alone did not affect the clinical outcomes such as OS and SAE during the systemic treatment in advanced NSCLC patients. However, it did influence the palliative care practices, resulting in a higher rate of hospital deaths.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
T.Yoshida.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10